About Theravance Biopharma
OUR FOCUS IS ON MAKING A DIFFERENCE
Theravance Biopharma, Inc. ("Theravance Biopharma") is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines. Its core purpose is to create medicines that help improve the lives of patients suffering from respiratory illness.
In pursuit of our purpose, Theravance Biopharma leverages decades of respiratory expertise to discover and develop transformational medicines that make a difference.
These efforts have led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its respiratory pipeline of internally discovered programs is targeted to address significant patient respiratory needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
Our Strategic Anchors
Focus on Insight and Innovation
Outsource Non-core Processes
Create and Foster an Integrated Environment
Aggressively Manage Uncertainty